Cutaneous Melanoma

  • Jeffrey E. GershenwaldEmail author
  • Geoffrey G. Giacco
  • Jeffrey E. Lee


According to the American Cancer Society, melanoma represents the sixth most commonly diagnosed cancer in the USA; approximately 76,250 individuals are expected to be diagnosed with invasive melanoma in 2012 [1]. Between 1975 and 2005, the annual incidence of invasive cutaneous melanoma in the USA rose by an average of 3.1 % per year, faster than that of nearly all other cancers [2, 3]. The estimated lifetime risk of developing cutaneous melanoma will be 1 in 50 by 2015 [2]. Moreover, recent data showed a real increase in incidence for both males and females, including young women. Also concerning is the finding that although the incidence of most cancers monitored by the surveillance, epidemiology, and end results (SEER) program has been decreasing, the incidence of melanoma has been increasing; in fact, the increase in the incidence of melanoma is the highest of all cancers, even among the subset of cancers that showed increasing incidence between 1995 and 2006 [2].


Cutaneous Melanoma Primary Melanoma Lymphatic Mapping Tumor Thickness Excision Margin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Cancer Society. Cancer facts and figures 2012. Atlanta: American Cancer Society; 2012. Accessed 13 Mar 2012.
  2. 2.
    Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975–2005. Bethesda: National Cancer Institute; 2008.Google Scholar
  3. 3.
    Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666–74.PubMedCrossRefGoogle Scholar
  4. 4.
    Gershenwald JE, Hwu P. Melanoma. In: Hong WK, Bast RC, Hait WN, et al., editors. Cancer medicine. 8th ed. Shelton: People’s Medical Publishing House; 2010. p. 1459–86.Google Scholar
  5. 5.
    Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRefGoogle Scholar
  6. 6.
    Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–83.PubMedGoogle Scholar
  8. 8.
    Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med. 2011;364:1738–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Staging of malignant melanoma. In: Manual for staging of cancer, 1st (revised) ed. Chicago: American Joint Committee on Cancer; 1978. p. 131–40.Google Scholar
  11. 11.
    Staging of malignant melanoma. In: Manual for staging of cancer, 1st ed. Chicago: American Joint Committee on Cancer; 1977. p. 131–6.Google Scholar
  12. 12.
    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.PubMedCrossRefGoogle Scholar
  13. 13.
    Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Balch CM. Melanoma of the skin. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2009.Google Scholar
  15. 15.
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48.PubMedGoogle Scholar
  16. 16.
    Ross MI. Surgery and other local-regional modalities for all stages of melanoma. Curr Opin Oncol. 1994;6:197–203.PubMedCrossRefGoogle Scholar
  17. 17.
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Ross M, Reintgen D, Balch C. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel lymph node biopsy in the management of early stage melanoma. Semin Surg Oncol. 1993;9:219–23.PubMedGoogle Scholar
  19. 19.
    Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253–60.PubMedGoogle Scholar
  20. 20.
    Ross MI, Thompson JF, Gershenwald JE. Sentinel lymph node biopsy for melanoma: critical assessment at its twentieth anniversay. Surg Oncol Clin N Am. 2011;20(1):57–78.PubMedCrossRefGoogle Scholar
  21. 21.
    Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011;104(4):341–53.PubMedGoogle Scholar
  22. 22.
    Caudle AS, Ross MI. Metastasectomy for stage IV melanoma: for whom and how much? Surg Oncol Clin N Am. 2011;20(1):133–44.PubMedCrossRefGoogle Scholar
  23. 23.
    Bedikian AY, Johnson MM, Warneke CL, et al. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol. 2008;5:201–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19.PubMedCrossRefGoogle Scholar
  25. 25.
    Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–57.PubMedCrossRefGoogle Scholar
  26. 26.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.PubMedCrossRefGoogle Scholar
  27. 27.
    Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.PubMedCrossRefGoogle Scholar
  28. 28.
    Gershenwald JE, Buzaid AC, Ross MI. Classification and staging of melanoma. Hematol Oncol Clin North Am. 1998;12:737–65.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Jeffrey E. Gershenwald
    • 1
    Email author
  • Geoffrey G. Giacco
    • 2
  • Jeffrey E. Lee
    • 1
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Tumor RegistryThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations